Vaid Ashok K, Khurana Aseem, Sharma Devender, Gautam Dheeraj, Wadhwa Jyoti, Agarwal Rajiv, Kaur Kanchan, Arora Jyoti, Gupta Kush
Medanta Cancer Institute, Medanta-The Medicity, Gurugram, India.
Medical Oncology, Sarvodaya Multispecialty and Cancer Hospital, Hisar, India.
World J Oncol. 2020 Jun;11(3):106-111. doi: 10.14740/wjon1284. Epub 2020 May 14.
The anthracycline and taxane-based chemotherapy treatment regimen remains the gold standard for treatment of early stage breast cancer. However, studies examining the effectiveness and use of this treatment regimen in Indian context are limited. This study examined patients treated with anthracycline and taxane-based chemotherapy at a tertiary care cancer center in India.
Patients with confirmed early stage breast cancer who had undergone primary breast surgery followed by treatment with anthracycline and taxane-based chemotherapy between 2009 and 2015 were included in the study. Data on clinical characteristics and treatment details were collected from the patients' medical records.
Two hundred sixty-four women were included in the analysis. The median age at presentation was 50 years. Among the 264 women, 40.5% were premenopausal, 1.2% were perimenopausal, and 58.3% were postmenopausal. The number of patients undergoing breast-conserving surgery (BCS) and modified radical mastectomy (MRM) were 35.2% and 64.7%, respectively. Patients with a tumor grade of 1, 2, and 3 were 7.2%, 53.1%, and 39.7%, respectively. Tumors were unifocal in 81.1% and multifocal in 18.2% of patients. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) positivity was detected in 58.3%, 54.2%, and 3.1% of patients, respectively and 38.6% of patients were triple negative. With a median follow-up of 36.2 months, the invasive disease-free survival rate was 90.9% and mean disease-free survival time was 65.4 ± 1.13 months.
The results of this study confirm the clinical utility of anthracycline and taxane-based chemotherapy regimen as the adjuvant chemotherapy treatment of early stage breast cancer.
基于蒽环类药物和紫杉烷的化疗方案仍是早期乳腺癌治疗的金标准。然而，在印度背景下研究该治疗方案有效性和使用情况的研究有限。本研究对印度一家三级护理癌症中心接受基于蒽环类药物和紫杉烷化疗的患者进行了检查。
本研究纳入了2009年至2015年间确诊为早期乳腺癌且接受了原发性乳房手术，随后接受基于蒽环类药物和紫杉烷化疗的患者。从患者病历中收集临床特征和治疗细节数据。
264名女性纳入分析。就诊时的中位年龄为50岁。在这264名女性中，40.5%为绝经前，1.2%为围绝经期，58.3%为绝经后。接受保乳手术（BCS）和改良根治性乳房切除术（MRM）的患者数量分别为35.2%和64.7%。肿瘤分级为1级、2级和3级的患者分别为7.2%、53.1%和39.7%。81.1%的患者肿瘤为单灶性，18.2%的患者为多灶性。分别在58.3%、54.2%和3.1%的患者中检测到雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER-2）阳性，38.6%的患者为三阴性。中位随访36.2个月，无侵袭性疾病生存率为90.9%，平均无病生存时间为65.4±1.13个月。
本研究结果证实了基于蒽环类药物和紫杉烷的化疗方案作为早期乳腺癌辅助化疗的临床效用。
